| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
BI2536-PEG2-Halo targets PLK1 (Polo-like kinase 1), a serine/threonine kinase essential for mitotic entry, centrosome maturation, bipolar spindle formation, and cytokinesis. PLK1 is overexpressed in many cancers and is a validated anti-cancer target. The HaloTag ligand moiety binds covalently to HaloTag protein (an engineered dehalogenase), allowing the conjugate to be selectively anchored to HaloTag-fused proteins (e.g., mutant p53). This restricts PLK1 inhibition to HaloTag-expressing cells, providing a proof-of-concept for targeted therapy.
|
|---|---|
| ln Vitro |
In vitro, BI2536-PEG2-Halo inhibits the proliferation of 293T cells expressing Halo-p53R273H(FL)-mCherry (p53 mutant) with an IC₅0 of 23 nM. Cells not expressing the HaloTag show much lower sensitivity (IC₅0 > 1 uM), demonstrating selective toxicity against p53-mutant cancer cells expressing the HaloTag. The compound inhibits PLK1 activity (as measured by reduced phosphorylation of PLK1 substrates such as Cdc25C and MYPT1) in HaloTag-expressing cells. The PEG2 linker provides flexibility and solubility. The compound is a research tool for validating molecular glue or targeted degradation strategies; it demonstrates that PLK1 inhibition can be selectively delivered to mutant p53-expressing cells via HaloTag conjugation.
|
| ln Vivo |
In vivo activity has not been reported; the compound is intended for cellular proof-of-concept studies. In principle, if a HaloTag-fused protein is expressed in tumors in vivo (e.g., via viral delivery or transgenic mouse), BI2536-PEG2-Halo could be used to achieve selective PLK1 inhibition in those tumors. However, this is not yet demonstrated.
|
| Enzyme Assay |
For cellular assays, 293T cells are transiently transfected with a construct encoding Halo-p53R273H(FL)-mCherry fusion protein. After 24-48 hours, cells are seeded in 96-well plates (5,000-10,000 cells/well) and treated with BI2536-PEG2-Halo (0.1 nM-10 uM) or vehicle (DMSO ≤0.1%) for 48-72 hours. Cell viability is assessed by MTT or CellTiter-Glo. IC₅0 values are calculated. For PLK1 activity, cells are treated with 50-500 nM compound for 4-24 hours, lysed in RIPA buffer, and Western blotted for p-Cdc25C (Ser216), p-MYPT1 (Thr696), and total PLK1. For apoptosis detection, Annexin V/PI staining and flow cytometry are performed. For HaloTag labeling, cells are incubated with a fluorescent HaloTag ligand (e.g., HaloTag TMR Ligand, 1-5 uM) for 30 minutes, fixed, and imaged by fluorescence microscopy to confirm HaloTag expression. For selectivity validation, control cells not expressing HaloTag are treated in parallel.
|
| Cell Assay |
Not applicable.
|
| ADME/Pharmacokinetics |
The compound is supplied as a powder soluble in DMSO (100 mg/mL). For in vitro use, prepare a 10 mM stock in DMSO. It is stable for 3 years at -20degC as powder, 6 months at -80degC in solution. No in vivo PK data are available.
|
| Toxicity/Toxicokinetics |
No toxicity data beyond cellular IC₅0. At 23 nM, the compound is non-toxic to cells lacking the HaloTag. Standard laboratory safety precautions: wear gloves, goggles, lab coat. Not for human use.
|
| References | |
| Additional Infomation |
BI2536-PEG2-Halo is a chemical probe for targeted PLK1 inhibition via HaloTag anchoring. It is a research tool, not an approved drug. For research use only.
|
| Molecular Formula |
C39H60CLN7O8
|
|---|---|
| Molecular Weight |
790.39
|
| Appearance |
White to off-white oil
|
| SMILES |
O=C(NCCOCCOCCC(NCCOCCOCCCCCCCl)=O)C1=CC=C(NC(N=C2N(C3CCCC3)[C@@H]4CC)=NC=C2N(C)C4=O)C(OC)=C1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~126.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (6.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (6.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2652 mL | 6.3260 mL | 12.6520 mL | |
| 5 mM | 0.2530 mL | 1.2652 mL | 2.5304 mL | |
| 10 mM | 0.1265 mL | 0.6326 mL | 1.2652 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
